# FDA warning letters on drug compounding: 24 since Nov 2024 Updated August 7, 2026. FDA issued 24 warning letters on drug compounding from December 17, 2024 to August 7, 2026, to 24 companies; 4 have a closeout letter. The newest, issued August 7, 2026 by the Center for Drug Evaluation and Research, went to Pine Pharmaceuticals, LLC (Compounding Pharmacy/Adulterated Drug Products). ## The full list FDA warning letters: drug compounding: 24 rows for $5, FDA warning letters issued November 12, 2024 to October 30, 2026. Columns: Company, Issue date, Posted, Issuing office, Subject, Subject group, Response letter posted, Closeout letter posted, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (issue date, subject group, response letter posted, closeout letter posted and read on), which open on your screen as soon as the payment clears and come by email. Buy: https://specstream.ai/data/fda-warning-letters/subject/compounding SpecStream is the live web data engine for teams and agents. It reads FDA's warning letters table each morning, and this page is that reading. Ask for the offices, subjects or companies you follow and each new letter arrives in your sheet, CRM, Slack or agent as FDA posts it. - Letters: 24 - With closeout: 4 - Latest issued: August 7, 2026 ## Newest letters The newest 24 of 24 by issue date, each linked to the letter on fda.gov. | Issued | Company | Issuing office | Subject | Posted | Source | | --- | --- | --- | --- | --- | --- | | August 7, 2026 | Pine Pharmaceuticals, LLC | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | October 6, 2026 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pine-pharmaceuticals-llc-728537-08072026) | | May 12, 2026 | Fagron BV | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | June 9, 2026 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fagron-bv-724551-05122026) | | April 7, 2026 | ProRx LLC | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | May 12, 2026 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-723704-04072026) | | March 20, 2026 | RC Outsourcing, LLC | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | April 21, 2026 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rc-outsourcing-llc-722877-03202026) | | February 9, 2026 | Thrive Health and Wellness, LLC dba Thrive Health Solutions | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | April 21, 2026 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-02092026) | | February 2, 2026 | Apollo Care, LLC | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | April 21, 2026 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/apollo-care-llc-715955-02022026) | | January 20, 2026 | GenoGenix LLC | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | March 3, 2026 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026) | | January 16, 2026 | Boothwyn Pharmacy, LLC | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | February 10, 2026 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/boothwyn-pharmacy-llc-717525-01162026) | | December 12, 2025 | MedisourceRx | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | February 24, 2026 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medisourcerx-717970-12122025) | | December 1, 2025 | Apothecary Pharma, LLC | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | March 17, 2026 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/apothecary-pharma-llc-717972-12012025) | | November 7, 2025 | Wells Pharma of Houston, LLC | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | November 25, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wells-pharma-houston-llc-713015-11072025) | | October 10, 2025 | PQ Pharmacy, LLC | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | December 2, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pq-pharmacy-llc-715795-10102025) | | September 22, 2025 | Revive Rx LLC dba Revive Rx Pharmacy | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | December 23, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/revive-rx-llc-dba-revive-rx-pharmacy-709509-09222025) | | September 16, 2025 | Turbare Manufacturing | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | December 2, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/turbare-manufacturing-713516-09162025) | | May 5, 2025 | Staska Pharmaceuticals, Inc. | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | July 1, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/staska-pharmaceuticals-inc-699291-05052025) | | April 23, 2025 | OSRX, Inc. | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | May 13, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/osrx-inc-701889-04232025) | | April 8, 2025 | Tailstorm Health Inc. dba Medivant Health | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | May 13, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailstorm-health-inc-dba-medivant-health-703497-04082025) | | April 2, 2025 | Empower Clinic Services, LLC dba Empower Pharmacy | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | April 29, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-700964-04022025) | | April 2, 2025 | Empower Clinic Services, LLC dba Empower Pharma | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | April 22, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharma-700962-04022025) | | March 5, 2025 | Annovex Pharma, Inc. | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | March 25, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/annovex-pharma-inc-698115-03052025) | | March 4, 2025 | ProRx, LLC | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | March 4, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-696742-03042025) | | January 22, 2025 | Nubratori, Inc. dba Nubratori Rx | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | April 15, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nubratori-inc-dba-nubratori-rx-700513-01222025) | | December 19, 2024 | Fagron Compounding Services, LLC dba Fagron Sterile Service | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | February 4, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fagron-compounding-services-llc-dba-fagron-sterile-service-698861-12192024) | | December 17, 2024 | Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals | Center for Drug Evaluation and Research | Compounding Pharmacy/Adulterated Drug Products | March 11, 2025 | [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/right-value-drug-stores-llc-dba-carie-boyd-pharmaceuticals-694687-12172024) | ## Subjects as FDA words them | Subject | Letters | Latest | | --- | --- | --- | | Compounding Pharmacy/Adulterated Drug Products | 24 | August 7, 2026 | ## By issuing office | Issuing office | Letters | Latest | | --- | --- | --- | | [Center for Drug Evaluation and Research](https://specstream.ai/data/fda-warning-letters/office/center-for-drug-evaluation-and-research) | 24 | August 7, 2026 | ## By year issued | Year | Letters | Latest | | --- | --- | --- | | [2025](https://specstream.ai/data/fda-warning-letters/year/2025) | 14 | December 12, 2025 | | [2026](https://specstream.ai/data/fda-warning-letters/year/2026) | 8 | August 7, 2026 | | [2024](https://specstream.ai/data/fda-warning-letters/year/2024) | 2 | December 19, 2024 | ## Where FDA publishes its warning letters - [FDA warning letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) Source: [FDA warning letters (U.S. Food and Drug Administration)](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters). Public domain (U.S. government work). Letters are as FDA lists them in its warning letters table: the company, the issue and posting dates, the issuing office and FDA's subject line. Subject groups are SpecStream's, read from the words of that subject line. FDA posts a letter some weeks after it issues it, so the newest weeks fill in later. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).